Premium
Treatment strategies in achieving remission in major depressive disorder
Author(s) -
Kelsey J. E.
Publication year - 2002
Publication title -
acta psychiatrica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.849
H-Index - 146
eISSN - 1600-0447
pISSN - 0001-690X
DOI - 10.1034/j.1600-0447.106.s415.4.x
Subject(s) - mirtazapine , clomipramine , antidepressant , venlafaxine , neurotransmitter , pharmacotherapy , major depressive disorder , psychology , venlafaxine hydrochloride , neurotransmitter systems , psychiatry , rating scale , medicine , pharmacology , receptor , anxiety , developmental psychology , cognition
Objective: This paper discusses strategies for achieving remission in major depressive disorder, summarizing the results of comparative studies of various antidepressants. Method: Antidepressant efficacy was determined as either response or remission, measured using the Hamilton Depression Rating Scale, the Clinical Global Impressions scale and other widely used instruments. Results: Study results suggest an advantage to pharmacotherapy that interacts with more than one neurotransmitter system, either as single mixed‐activity drugs (e.g. clomipramine, mirtazapine and venlafaxine extended‐release) or combinations of medications that are individually specific for a single neurotransmitter system. Conclusion: Remission should be the goal of antidepressant therapy. Treatment strategies include increasing the dosage of the chosen antidepressant; switching to an antidepressant with a different mechanism of action; augmenting one antidepressant with another agent; or using combination therapy. A substantial body of data indicates that for a subset of depressed patients, activation of multiple neurotransmitter systems is beneficial in achieving remission.